From: Mortality rate among HIV-positive children on ART in Northwest Ethiopia: a historical cohort study
Variables | Frequency (N) | Percentage (%) |
---|---|---|
OI at baseline | ||
 Yes | 242 | 45.0 |
 No | 296 | 55.0 |
Functional status (age ≥ 5 years) (N = 347) | ||
 Working | 195 | 56.2 |
 Ambulatory | 144 | 41.5 |
 Bedridden | 8 | 2.3 |
Developmental history (age < 5 years) (N = 191) |  |  |
 Appropriate | 143 | 74.9 |
 Delayed | 40 | 20.9 |
 Regressive | 8 | 4.2 |
WHO clinical staging | ||
 Stage I and II | 310 | 57.6 |
 Stage III and IV | 228 | 42.4 |
Past TB test before ART | Â | Â |
 Not determined | 430 | 80.0 |
 Negative | 53 | 9.9 |
 Positive | 55 | 10.1 |
Past TB treatment | ||
 No treatment | 483 | 89.8 |
 2SRHZ/4RH | 38 | 7.1 |
 2HRZES/4HRE | 4 | 0.8 |
 HRZE/4RH | 13 | 2.4 |
CD4 count or percent | ||
 Severe immunodeficiency | 374 | 69.5 |
 Mild immunodeficiency | 164 | 30.5 |
Hemoglobin level | ||
 Anemic(< 10 g/dl) | 66 | 12.3 |
 Non-anemic (≥10 g/dl) | 472 | 87.7 |
ART eligibility criteria | ||
 Immunologic/ CD4 | 134 | 24.9 |
 WHO clinical stage | 67 | 12.5 |
 Both clinical and immunologic | 216 | 40.2 |
 Test and treat approach | 121 | 22.5 |
Cotrimoxazole preventive therapy | ||
 Yes | 340 | 63.2 |
 No | 198 | 36.8 |
ART adherence in the 1st 3 months | ||
 Good /fair | 495 | 92.2 |
 Poor | 42 | 7.8 |
Underweight (baseline) | ||
 Normal | 317 | 58.9 |
 Moderate (WAZ < - 2) | 128 | 23.8 |
 Severe (WAZ < −3) | 93 | 17.3 |
Stunting (baseline) | ||
 Normal | 336 | 62.5 |
 Moderate (HAZ < −2) | 80 | 14.9 |
 Severe (HAZ < −3) | 122 | 22.7 |
Wasting (baseline) | ||
 Normal | 365 | 67.8 |
 Moderate (WHZ or BAZ < −2) | 83 | 15.4 |
 Severe (WHZ or BAZ < − 3) | 90 | 16.7 |